CancerIQ Secures $14M for AI Detection

- The $14 million Series B funding round was co-led by Merck Global Health Innovation Fund and Amgen Ventures, with participation from McKesson Ventures, OSF Ventures, and HealthX Ventures. This capital is aimed at expanding CancerIQ's health system network and partnerships to democratize access to the latest innovations in early cancer detection. - The company's platform integrates into electronic health record (EHR) workflows, allowing clinicians at over 180 locations to determine a patient's cancer risk based on family history, genetics, and behavior, and then connect them to personalized care pathways. Recent partnerships include collaborations with Azra AI for lung cancer screening and iCAD to create a comprehensive breast health solution. - Founder Dr. Olufunmilayo Olopade is a MacArthur "Genius Grant" recipient and a distinguished professor at the University of Chicago, renowned for her research on the genetic basis of breast cancer in women of African ancestry. Her work has been pivotal in understanding the molecular genetics of aggressive breast cancers and translating those findings into clinical practice. - For direct-to-consumer health apps, HIPAA compliance generally applies only if the app is provided by a "covered entity" like a doctor or insurer, or if it handles protected health information (PHI) on their behalf. Apps that collect health information directly from consumers often fall outside of HIPAA's scope but are subject to the FTC's Health Breach Notification Rule. - The digital health funding market saw a significant rebound in 2025, reaching $14.2 billion, a 35% increase from 2024. This growth was driven by larger, concentrated investments in AI-enabled companies, which captured 54% of total funding and commanded a 19% premium on average deal size compared to non-AI startups. - Startups in the longevity and biohacking space are attracting significant investment by focusing on extending healthspan through cellular rejuvenation, epigenetic reprogramming, and AI-driven drug discovery. Companies like Altos Labs and Cambrian Bio are pioneering therapies that target the root causes of aging. - In the consumer health tech landscape, wearable devices are increasingly integrated into clinical care for remote patient monitoring and chronic disease management. Startups are leveraging data from wearables with AI and machine learning to create personalized health interventions and predictive analytics for conditions ranging from cardiac arrhythmias to mental health.